PatentChecker
Demo: CRISPR IP drift posture report
A single-page posture report generated deterministically from Evidence Packets: baseline → delta → actionable queues.
This is in silico sequence monitoring. It is not legal advice and not an infringement/FTO conclusion.
Report header
tool_version: 0.1.26
contract_version: v0.1.26
contract_hash: sha256:7440ecbbe1df3b3e43a846b0bf03c4ee9d42ec9ab76d638bedf2e949d6d7d88a
watchlist_id: wl_demo_crispr_guide_001
watchlist_sha256: sha256:1ac864df49ae7077eb162ec4697ab1889c7f1750204676859c064757826feed3
corpus_snapshot_ids: uspto_us_2015-2025_2025-01-01
run: run_2025-01-01T000000Z_demo_crispr_guide @ 2025-01-01T00:00:00Z
Interpretation guardrails
- Match indicates similarity under configured method
- Outputs are informational; not legal advice
- Not an infringement or Freedom-to-Operate (FTO) determination
- Claim scope review required before action
Current posture (one page)
Rows are stably ordered by family_id. Fresh-look triggers are explicit enums to avoid ambiguity.
| Family | Severity | Owner | What changed | Why it matters | Recommended action |
|---|---|---|---|---|---|
| US-CRISPR-FAM-001 | HIGH | Broad Institute, Inc. competitor watch | new_publicationroi_overlap_delta new_publication(US2024000100); roi_overlap_delta(0.63→0.40) | High-similarity competitor family with fresh-look triggers; prioritize claim scope review. | Triage ticket: counsel + R&D (claim scope + design-around). |
| US-CRISPR-FAM-002 | MEDIUM | University of California; University of Vienna competitor watch | no material delta | No material delta detected; keep under watch. | Monitor: no material delta. |
| US-CRISPR-FAM-003 | HIGH | Editas Medicine, Inc. portfolio watch | new_publicationnew_family_detected new_publication(US2023000300); new_family_detected(HIGH,id=0.91,qcov=0.82) | Internal portfolio activity detected for governance/annotation (not an external risk conclusion). | Portfolio watch: annotate as internal activity; route to portfolio owner. |
| US-CRISPR-FAM-004 | MEDIUM | Intellia Therapeutics, Inc. competitor watch | new_publicationnew_family_detected new_publication(US2024000456); new_family_detected(MEDIUM,id=0.84,qcov=0.65) | Competitor posture changed in a counsel-relevant way (publication or band/family change). | Counsel review: assess claim scope and program relevance. |
Queues
Open actions
2 items
- US-CRISPR-FAM-001 — Triage ticket: counsel + R&D (claim scope + design-around).
- US-CRISPR-FAM-004 — Counsel review: assess claim scope and program relevance.
Monitoring only
1 items
- US-CRISPR-FAM-002 — Monitor: no material delta.
Portfolio watch
1 items
- US-CRISPR-FAM-003 — Portfolio watch: annotate as internal activity; route to portfolio owner.